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Summary. There has been some recent work in the statistical literature for modeling the relationship
between the size of cancers and probability of detecting metastasis, i.e., aggressive disease. Methods for
assessing covariate effects in these studies are limited. In this article, we formulate the problem as assessing
covariate effects on a right-censored variable subject to two types of sampling bias. The first is the length-
biased sampling that is inherent in screening studies; the second is the two-phase design in which a fraction of
tumors are measured. We construct estimation procedures for the proportional hazards model that account
for these two sampling issues. In addition, a Nelson–Aalen type estimator is proposed as a summary statistic.
Asymptotic results for the regression methodology are provided. The methods are illustrated by application
to data from an observational cancer study as well as to simulated data.
Key words: Biased sampling; Empirical process; Inverse probability weighting; Natural history; Screening
program.
1. Introduction
Given the morbidity and mortality and associated costs of
treating people with cancer, it is important to determine op-
timal screening schedules for early detection of cancer. There
has been much work done on developing mathematical mod-
els of screening (Yakovlev and Tsodikov, 1996, Chapter 5).
Much of the previous work in this area has focused on consid-
eration of multistate models (Zelen and Feinleib, 1969; Albert,
Gertman, and Louis, 1978; Day and Walter, 1984; Shen and
Zelen, 1999). Based on the estimated parameters from the
model, one can then begin to assess effects of screening inter-
ventions on these quantities. More recent work has focused
on estimating operating characteristics of screening programs
(e.g., Baker, Erwin, and Kramer, 2003).
An alternative approach is to better understand the rela-
tionship between various aspects of tumor biology and pro-
gression. Such procedures have been proposed by Kimmel and
Flehinger (1991) and Xu and Prorok (1997, 1998) in the one-
sample setting. In many situations, it is of interest to deter-
mine the effects of covariates on tumor progression. Such a
question requires a regression formulation. Recently, an ap-
proach to this problem has been outlined by Ghosh (2006).
The regression model utilized there was the additive haz-
ards model (Breslow and Day, 1980; pp. 53–57). However,
much more popular for the analysis of failure time data is the
proportional hazards regression model (Cox, 1972). For that
model, the regression parameters are interpretable as relative
risk ratios on a logarithmic scale, which are easily compre-
hended by epidemiologists.
One issue with tumor data from screening trials is that of
length-biased sampling (Zelen and Feinleib, 1969; Patil and
Rao, 1978). Because of lead-time bias due to screening, the
types of tumors that are detected tend to be smaller and
slower-growing tumors. In the initial work of Kimmel and
Flehinger (1991), it was assumed that there was no biased
sampling. While the proportional hazards regression model
for length-biased data has been studied by Wang (1996), she
did not consider the presence of censoring, which is present
in the data we consider here.
Another complication in the collection of tumor data is that
only a fraction of tumors have size measurements. The way
this was incorporated by Kimmel and Flehinger (1991) is to
assume that the missingness mechanism for the distribution
of tumor sizes is missing completely at random (Little and
Rubin, 2002). This issue is not addressed in the statistical
framework of Ghosh (2006). It seems that this might not be a
completely reasonable assumption. A more realistic scenario
is to assume that the tumors that tend to be measured are a
function of observed covariates.
In this article, we develop estimation procedures for the
analysis of tumor size–metastasis data in cancer studies. The
course of this article is as follows. In Section 2, we state
the model for tumor size and progression and briefly review
the results of Kimmel and Flehinger (1991). We will also
discuss the notion of time scales and induced dependent cen-
soring for this problem. It turns out that some further as-
sumptions are needed to ensure the validity of one class of the
estimators proposed by Kimmel and Flehinger (1991). Semi-
parametric inference procedures for the proportional hazards
model with length-biased data under a deterministic growth
assumption will be outlined in Section 3. While the method
of Wang (1996) has been proposed for length-biased data, it
cannot be directly applied for censored data. In this article,
we construct a new estimation procedure based on estimat-
ing equations; asymptotic results are provided as well. We also
describe the extension to accommodate nonmeasured tumors.
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The proposed methods are then applied to data from a lung
cancer screening study in Section 4. The finite-sample proce-
dures of the proposed methods are also assessed using a small
simulation study. In addition, we assess the sensitivity of in-
ferences to violations in model assumptions using simulation
studies as well. Finally, we conclude with some discussion in
Section 5.
2. Tumor Screening Framework
2.1 Notation and Model Assumptions
Let S denote the tumor size, δ be an indicator of metastasis
(i.e., δ = 1 if the tumor has metastasis and zero otherwise) and
Z represent a p × 1 vector of covariates. For i = 1, . . . ,n, the
observed data consist of {Si , δi, Zi}, n independent copies
from {S, δ, Z}. We will also assume that there is a single
screening exam given.
In their framework, Kimmel and Flehinger (1991) make the
following model assumptions:
(a) Primary cancers grow monotonically, and metastases are
irreversible.
(b) Denote Y as the random variable for the distribution of
the primary tumor sizes at which metastatic transitions
take place. Let the CDF of Y be denoted by FY .
(c) Let λd1 (x) denote the hazard function for detecting a can-
cer with metastasis when the tumor size is x. Let λd0 (x)
denote the hazard function for detecting a cancer with
no metastases when the tumor size is x. Assume that
λd1 (x) ≥ λd0 (x).
Note that in Assumption (b), we define metastatic transition
as the point at which the metastasis can become detectable
using existing diagnostic methodologies. Under Assumptions
(a)–(c), Y defines a time scale; however, its distribution is
not identifiable with the observed data (S, δ, Z). Kimmel and
Flehinger (1991) describe two scenarios in which FY , the dis-
tribution function of Y, is identified from the observed data.
The first is when cancers are detected immediately when the
metastatic transition occurs. The second is when the detec-
tion of the cancer is not affected by the presence of metastases.
We will refer to these as Models I and II. In Ghosh (2006),
it is shown that Model I corresponds to treating S as a right-
censored version of Y. Here and in the sequel, only Model I is
considered. Conceptually, the data are cross-sectional; we do
not consider any followup on the subjects as in other preva-
lent cohort setting (e.g., Asgharian and Wolfson, 2005 and the
references therein).
The effect of Z on Y is formulated through the proportional
hazards model:





where λ(· |Z) is the hazard function conditional on covariates,
λ0(·) is an unspecified baseline hazard function, and β 0 is a
p × 1 vector of unknown regression coefficients.
2.2 Time Scales and Induced Dependent Censoring
What the Kimmel–Flehinger framework corresponds to is us-
ing a different time scale for analysis. The scale is that defined
by the size of the tumor. We briefly discuss the utility of the
time scale being used here and bring up a crucial point in-
volving induced censoring.
Let T denote the time at which the tumor becomes
metastatic and is potentially detectable by diagnosis. This
occurs on the chronological time scale. However, in screen-
ing trials, there is a time zero representing start of study,
and screening exams occur after the study begins. Thus,
the screening exam times are assessed on the study time
scale. The assumptions of Kimmel and Flehinger (1991) de-
fine Y ≡ φ(T) as a new time scale. A question then becomes
in what sense will Y be fully informative about T. This can
be answered by utilizing the notion of an ideal time scale
(Duchesne and Lawless, 2000). Y is an ideal time scale if
Pr(Y > y) = Pr(T > φ−1 (y)) and φ is a monotonic func-
tion, i.e., T and Y generate the same survivor functions.
It turns out that the validity of the estimation procedures
proposed by Kimmel and Flehinger rests on the following ad-
ditional assumptions:
A. φ is a deterministic and monotonic function of time.
B. There exists a single exam time.
C. The distribution of time of progression to metastasis is
independent of age at study entry.
Assumption A is needed to avoid the problem of induced de-
pendent censoring. Intuitively, tumor size is really a stochastic
process over time. If C denotes time to the screening exam,
then what we observe is S(C ∧ T), which might still be depen-
dent even if T and C are independent. Condition A is suffi-
cient to guarantee independence and implies that Y and T are
ideal time scales as described above. This implies that viola-
tion of Assumption A leads to bias in the Kimmel–Flehinger
estimator of the distribution tumor size at metastasis if no
information on time is provided. However, this assumption is
restrictive; it means that if two tumors have the same time to
metastasis, then they have the same tumor size. This seems
to be a highly implausible assumption; in the Discussion, we
discuss relaxation of this assumption.
The second condition is needed to provide a simple defini-
tion of the censoring time here. Potentially, this assumption
can be relaxed if screening is defined by a schedule of exami-
nation times t1, . . . , tM . Then, we would need to assume that
the examination time process is independent of T.
Finally, Condition C is needed to account for the fact that
subjects who enter the screening trial may have tumors that
are in the undetectable preclinical phase. In fact, the estima-
tors proposed by Kimmel and Flehinger (1991) presume that
the induced time scale for size equals zero at the start of the
study. This is more restrictive than Condition C, a more re-
alistic assumption that would not affect the validity of the
Kimmel–Flehinger estimators. In this instance, the Kimmel–
Flehinger estimators are in effect estimating a truncated dis-
tribution function of tumor size at the metastatic transition
point. A violation of the assumption is when the distribu-
tion of tumor sizes is age dependent. This again renders the
estimation methodology invalid.
2.3 Length-Biased Sampling
Another complication in analyzing tumor size data is the pres-
ence of length-biased sampling. What this means is that the
tumors detected in a screening program tend to be slower-
growing tumors. In terms of the probability model being con-
sidered, we now have the additional sampling mechanism to
deal with, in addition to (1):





where w(y) is a known positive and increasing weight func-
tion. In the absence of covariates, one-sample estimation pro-
cedures have been considered by Cox (1969), Vardi (1982),
and Jones (1991). The semiparametric model (1) subject to
length-biased sampling, with w(y) = y in (2), has been con-
sidered by Wang (1996). However, in that proposal, there was
no censoring. In addition, we have to deal with the issue that
only a fraction of tumors are measured.
The probabilistic model (2) with w(y) = y is consistent with
the distribution of interevent times in the so-called positive
stable disease model (Day and Walter, 1984). We study the ef-
fects of misspecification in the simulation studies in Section 5.
3. Estimation Procedures for Uncensored
and Censored Data
3.1 Regression Methodology
In this section, we will describe estimation procedures for the
semiparametric proportional hazards regression model assum-
ing that tumor size is a monotonic and deterministic function
of time to tumor metastasis. We first start with the case of
all tumors being measured, followed by the situation where
a subset of tumors is measured. While the problem of esti-
mation in (1) with length-biased data has been considered by
Wang (1996), there was no censoring in her situation (i.e.,
Y ≤ C with probability one). In the data we collect, an added
complication is that censoring is present. The censoring rep-
resents tumors detected by screening but which do not have
metastases. As will be shown later, the estimation procedure
of Wang (1996) cannot be directly applied for this situation.
To construct the proposed estimation procedure, we begin
by considering the case of no censoring. We slightly general-
ize the results of Wang (1996) to an increasing and positive
function w(y). Let N ∗i(t) = I(Yi ≤ t) and R∗i(t) = I(Yi ≥ t),
i = 1, . . . ,n. In Wang (1996), it is shown that the process
M ∗i (t;β)









λ0(u)du (i = 1, . . . , n)
(3)
is a martingale. The quantity (3) motivates the following esti-



























Define β̂ to be the estimator derived from setting (4) equal
to zero. By standard martingale arguments (Andersen et al.,
1993), the random vector n1/2(β̂ − β0) converges in distribu-
tion to a p-dimensional normal random vector with mean zero




















with a⊗2 =aaT . We now consider the situation where both
Y and C are known. Note that this is an artificial situation,
but it will motivate our proposed estimation procedure. For
this scenario, the process Mi(t;β0) ≡
∫ t
0 I(Ci ≥ u)dM i(t;β0)
(i = 1, . . . , n) will also be a zero-mean process. Simple alge-



























where Ni(t) = I(Yi ≤ t, δi = 1), to be a valid estimating func-
tion for β. However, because we do not observe either Y or
C completely, (5) cannot be used as an estimating function
for β based on the observed data. To be specific, if we replace
w(Y) by w(S) in (5), then it is no longer a zero-mean estimat-
ing function for β. Our approach is to modify it; we need to
replace I(Si ≥ t)/w(Yi ) in (5) by an observable quantity with


























































where GC (t) ≡ Pr(C > t) is the survival function for
C. Thus, the observable quantity I(Si ≥ t)δi/w(Yi )GC (Yi )
(i = 1, . . . ,n) has the same expectation as I(Si ≥ t)/w(Yi ).
Because GC is unknown, we replace it by its estimator based






















where Rj (t) = I(Sj ≥ t), j = 1, . . . ,n. The constant τ > 0 is
chosen to satisfy GC (τ) > 0. Let β̃ denote the solution from
setting Ũ(β) = 0. The relevant zero-mean process correspond-
ing to (6) is








i = 1, . . . , n. Note that we cannot directly apply martingale
theory as before to derive the consistency and asymptotic nor-
mality of β̃ because of the GC and δ in (7). However, (7) re-
mains a valid zero-mean process for β = β0. In the Appendix,
given in the Supplementary Materials, we prove the following
theorem:
Theorem 1: Assuming certain regularity conditions, given
in the Appendix, the estimator β̃ is strongly consistent, i.e.,
β̃ →a.s. β0. Furthermore, the random vector n1/2(β̃ − β0) con-
verges in distribution to a zero-mean normal random vector with
a covariance matrix that can be consistently estimated by I−1
SI−1, where









{Zi − Z̃(t; β̃)}⊗2dM i(t; β̃).
Note that (6) falls into the class of inverse probability of
censoring weighted (IPCW) estimating equations studied by
Robins and colleagues (e.g., Robins and Rotnitzky, 1992).
There are several ways in which (6) could be extended. For ex-
ample, we can model the censoring based on covariates. For
example, if Z consists of discrete covariates, then we could
plug in covariate-specific Kaplan–Meier estimators for cen-
soring into (6). A generalization that adjusts for discrete and
continuous covariates is via a stratified proportional hazards
model for censoring:
λC(t |Z,W) = λC0w(t) exp(γT Z),
where W is a set of discrete covariates, the combination of
whose values defines the strata for the model. Based on the
estimates from the model, one can compute individual-specific
censoring probabilities and plug them into (6); this is the
approach taken in Robins and Rotnitzky (1992). One could
also derive the so-called “doubly robust” estimating functions
using techniques from van der Laan and Robins (2003). These
extensions are beyond the scope of this article.
A generalization of the estimating equation is to consider






H(β, t){Zi − Z̃(t;β)} dNi(t), (8)
where H(β, t) is a data-dependent weight function. Ideally,
H(β, t) would be chosen in a manner to maximize the effi-
ciency of the resulting solution from setting (8) equal to zero.
However, the optimal weight function in (8) will be difficult
to find because it will depend on the weight function in (2)
as well as the censoring distribution. Both of these quantities
are unknown.
3.2 Baseline Hazard Estimation
In usual survival analysis problems with right-censored data,
graphical summaries are given by Kaplan–Meier or Nelson–
Aalen estimators. For the setting proposed here, such tech-
niques have not been available. We can use (7) to motivate a
Nelson–Aalen type estimator that can be used for giving a de-

















Plugging in an estimator of GC into (9) gives a Nelson Aalen-
type estimator for Λ0(t). The resulting estimator has a form
very similar to that of the usual Nelson–Aalen estimator for
right-censored data. The major difference is that the risk set
in the denominator of (9) has a much more complicated form
to account for the length-biased sampling and censoring.
3.3 Estimation for Two-Stage Design
We now incorporate the fact that (S, Z) is not collected on all
tumors. The design of the study is treated as two-stage sam-
pling; this type of design is very common in survey sampling
studies. Let D denote the indicator of selection of the tumor
into the second stage of the study. We make two assumptions
about selection into the second stage. First, we assume that
D is conditionally independent of S given Z. However, we do
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allow the probability of inclusion into the second stage to de-
pend on Z; denote this as π(Z) ≡ P (D = 1 |Z). The following






















for j = 1, . . . ,n. Let β̃c denote the solution from setting
Ũc(β) = 0. It can be shown using arguments in Lin (2000)
that β̃c is consistent for β0 and that n
1/2(β̃c − β0) is asymp-
totically normal. The form of the variance of the limiting dis-
tribution is similar to that for estimators of the proportional
hazards model under case–cohort sampling (Barlow, 1994).
We have utilized the jackknife in order to estimate the vari-
ance of β̃c (Lipsitz, Dear, and Zhao, 1994).
4. Numerical Examples
4.1 Lung Cancer Data
In this section, we apply the proposed methodology to data
from a screening trial involving lung cancer and reported in
Kimmel and Flehinger (1991). The lung cancer data were col-
lected on a population of male smokers over 45 years old en-
rolled in a clinical trial involving sputum cytology. There are
two types of lung cancer diagnosed, adenocarcinomas (can-
cers that originate in epithelial cells) and epidermoid cancer
(cancers that originate in the epidermis). For the adenocar-
cinomas, they were detected by radiologic screening and by
symptoms; the epidermoids were detected by sputum cytol-
ogy or by chest X-ray. The presence or absence of metasta-
sis was determined using available staging, clinical, surgical,
and pathological readings. There are 141 adenocarcinomas, of
which 19 have metastases; of the 87 epidermoid cancers, six
have metastases. There are also nonmeasured tumors which
account for the two-phase design we described; the missing
data measurements are summarized in Table 1. It is of in-
terest to determine if there is an association between site of
origin and aggressiveness of tumor. Thus, there is a single co-
variate Z, site of origin. We code it 0/1 for adenocarcinomas
and epidermoids, respectively. The data on tumor sizes are
Table 1
Summary of lung cancer data
Adenocarcinomas Epidermoids
Status Metastatic Nonmetastatic Metastatic Nonmetastatic
Measured 19 122 6 81
Not measured 15 8 12 12
Note: Status refers to whether or not the tumor size is measured; not measured tumors


















Figure 1. Boxplot of tumor sizes for lung cancer screening
data.
shown in Figure 1. Recall that the tumor size will be used as
a failure time variable. Based on the plot, we find evidence
that the epidermoids have larger tumor sizes. However, this
graph does not incorporate the censoring or the length-biased
sampling. In all analyses reported in this section, the weight
function w(y) = y is used.
Next, we consider Nelson–Aalen estimators of the tumor
size distributions; these are given in Figure 2. The plots sug-
gest that epidermoids are at increased risk of metastasizing
relative to adenocarcinomas. However, the difference appears
less in Figure 2a than in Figure 2b. However, the estimated
risk of metastasis for adenocarcinomas in Figure 2b appears
to be very close to zero, which suggests that there might
be substantial variability in this estimate. Note also that in
Figure 2b, there appears to be less evidence for proportional
hazards, accounting for the length-biased sampling.
We first use the analysis method outlined in Ghosh (2006).
This corresponds to treating the tumor size as a right-
censored random variable and fitting a proportional hazards
analysis that ignores the biased sampling and the two-stage
design. This can be fit using existing survival analysis soft-
ware for the Cox model and yields an estimated relative risk
of exp(0.56) = 1.76 with an associated 95% confidence interval
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Figure 2. Nelson–Aalen estimators for the cumulative haz-
ard function corresponding to distribution of tumor size at
metastatic transition. Solid line is for the epidermoid cancers,
while dashed line is for the adenocarcinomas. (a) The esti-
mators when tumor size is treated as right-censored random
variable, and the length–biased sampling mechanism is ig-
nored. (b) Based on treating the tumor size as a right-censored
random variable with the length-biased sampling mechanism
incorporated. All estimators ignore the two-phase sampling.
(CI) of (0.79, 3.93). Thus, while the epidermoid tumors tend
to have smaller sizes for detectable metastasis, the association
is not statistically significant. Next, we present the analysis
which ignores the nonmeasured tumors and incorporates the
biased sampling aspect. This corresponds to the method de-
scribed in Section 3.1. This analysis gives an estimated rel-
ative risk of exp(0.16) = 1.17 with an associated 95% CI
of (0.51, 2.73). Thus, the epidermoids have increased risk of
smaller tumor size for detectable metastasis in this analysis
as well. However, incorporating the length-biased sampling
mechanism leads to a 33% reduction in the relative risk, al-
though the association is still nonsignificant.
Finally, we present results of regression models in which the
two-phase sampling is taken into account. The first analysis
ignores site of origin; this corresponds to treating π(Z) = 0.82.
This analysis gives an estimated relative risk of exp(0.12) =
1.13 with an associated 95% CI of (0.52, 2.42). The second
analysis allows for different sampling weights based on site of
origin; based on the data in Table 3, this yields π(Z) = 0.86
and 0.78 for adenocarcinomas and epidermoids, respectively.
This analysis gives an estimated relative risk of exp(0.15) =
1.16 with an associated 95% CI of (0.55, 2.45). In this in-
stance, it does not appear that incorporating the case–control
sampling into the analysis appears to change the answer sub-
stantially.
Table 2
Summary of simulation results for β
U(0,2) censoring U(0,6) censoring
n Bias SE SEE CP Bias SE SEE CP
50 −0.01 0.59 0.55 0.92 −0.04 0.49 0.45 0.93
100 −0.02 0.39 0.37 0.94 −0.02 0.34 0.32 0.94
200 0.01 0.31 0.30 0.95 −0.01 0.24 0.24 0.95
Note: Bias is the mean of the estimators of θ0 minus θ0; SE is
the standard error of the estimators of θ0; SEE is the mean of the
standard error estimate; and CP is the coverage probability of the 95%
confidence interval.
4.2 Simulation Studies
To assess the finite-sample properties of the regression esti-
mation methodology from Section 3.1, we performed a series
of simulation studies. We let Z ≡ Z denote a binary indicator
and used the same simulation setup as in Wang (1996). In
particular, we took the density for Z = 0 to be
f0(y) = 2ye−y
2
, y > 0
and that for Z = 1 to be
f1(y) = 2e
βye−e
βy2 , y > 0.
Thus, the hazard ratio between the two groups is β; in the
simulations, we considered β = 2. Length-biased sampling
was incorporated using w(y) = y and was independent of the
group. Two types of censoring were considered. In the first,
U(0, 2) random variables were used for independent censoring,
while in the second situation, U(0, 6) random variables were
generated. This yielded approximately 50% and 20% censor-
ing, respectively. For each simulation scenario, 500 data sets
were generated. Sample sizes n = 50, 100, and 200 were con-
sidered. The results are given in Table 2. Based on the simu-
lation results, the proposed estimation procedure appears to
have satisfactory performance for the sample sizes considered,
with diminishing bias for larger sample sizes.
We also studied a situation in which the data are generated
using the same mechanism, but in which we fit the estimating
equation using w(y) = y2. This was done in order to study the
effects of misspecification in the estimation procedure. The
same simulation settings were used as before; the results are
given in Table 3. Based on the table, we find that for larger
sample sizes, the estimators show greater bias and worse cov-
erage probabilities for the 95% confidence intervals.
Table 3
Summary of simulation results for β under misspecification
U(0,2) censoring U(0,6) censoring
w(y) n Bias SEE CP Bias SEE CP
y2 50 −0.18 0.82 0.91 −0.08 1.07 0.93
100 −0.25 0.57 0.81 −0.26 0.72 0.84
200 −0.30 0.44 0.75 −0.36 0.24 0.74
Note: See Note to Table 2. w(y) denotes the weight function used in
the estimating equation procedure.
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5. Discussion
In this article, we have presented a general framework to the
analysis of data from cancer studies using the proportional
hazards model. More generally, this article provides a new way
of thinking about such data. Provided one can make mono-
tonicity assumptions such as those outlined in Kimmel and
Flehinger (1991), one can analyze data on the time scale de-
fined by the evolution of the tumor. Such assumptions can
help provide information on the natural history of the disease
as well as on the kinetics of progression. Novel features of the
data not fully addressed before include the presence of length-
biased sampling, right censoring, and the two-phase design of
the study.
Another bias in screening studies is lead-time bias, in which
the tumor is detected by screening but might potentially
have no survival benefit. There are two potential extensions
of this model to incorporate lead-time bias. One is to as-
sume that lead-time bias detects all tumors at a size that is
smaller than it would otherwise be. This would impose con-
straints on the form of w in (2). Another is to assume that
lead-time bias would have no effect on tumor size of tumors
that have metastasized but would detect a nonmetastatic tu-
mor at a smaller tumor size than would be otherwise ex-
pected. For this situation, it would be possible to estimate
the function w in (2). Both avenues are worthy of further
exploration.
Throughout this article, we have assumed that the weight
function in the length-bias sampling mechanism was known.
It might be possible to estimate w if we change model
assumptions, described at the beginning of this section, or
if we attempted to incorporate tumor size/metastasis infor-
mation from interval detected cases (cases detected by means
other than screening between screening examinations). With-
out such data, the choice of w will typically depend on prior
scientific or mechanistic considerations.
The estimation procedure described here for the propor-
tional hazards regression model with right-censoring and
length-biased sampling is novel. Proving asymptotic results
about the estimators of the regression coefficients requires the
use of modern empirical process techniques.
Finally, we have also shown that the Kimmel–Flehinger
model for the Case I scenario is only valid under very restric-
tive assumptions, described in Section 2.3. One method of
relaxing this assumption, suggested by a referee, is to allow φ
to be subject specific, i.e., each subject has a specific growth
function φi(t) (i = 1, . . . ,n). To make estimation feasible, we
will need to specify a model for (φ1, . . . ,φn), potentially as a
function of covariates or by specifying a probability distribu-
tion for them. An alternative is to employ the Case II sce-
nario from Ghosh (2006). However, this requires treating the
tumor size data as interval-censored random variables that
are subject to length-bias sampling, which is a much more
complicated data structure.
6. Supplementary Materials
The Web Appendix referenced in Section 3.1 is available un-
der the Paper Information link at the Biometrics website
http://www.tibs.org/biometrics.
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